ACADIA Pharmaceuticals - Stock Price History | ACAD

Historical daily share price chart and data for ACADIA Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for ACADIA Pharmaceuticals as of September 27, 2021 is 17.41.
  • The all-time high ACADIA Pharmaceuticals stock closing price was 57.00 on July 07, 2020.
  • The ACADIA Pharmaceuticals 52-week high stock price is 57.46, which is 230% above the current share price.
  • The ACADIA Pharmaceuticals 52-week low stock price is 15.68, which is 9.9% below the current share price.
  • The average ACADIA Pharmaceuticals stock price for the last 52 weeks is 34.03.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
ACADIA Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 45.5323 41.1100 57.0000 31.6500 53.4600 24.96%
2019 30.7888 16.6500 51.4000 16.1700 42.7800 164.56%
2018 20.0978 30.4300 32.3300 13.0300 16.1700 -46.30%
2017 32.3912 28.7700 39.8500 25.4500 30.1100 4.40%
2016 29.0100 34.6200 41.5500 17.2600 28.8400 -19.10%
2015 37.5110 31.1500 50.1000 30.3700 35.6500 12.28%
2014 24.4843 25.1500 32.9800 17.8200 31.7500 27.05%
2013 16.2624 4.7300 28.8400 4.7300 24.9900 437.42%
2012 2.0785 1.1100 5.4300 1.0900 4.6500 330.56%
2011 1.5292 1.2200 2.9400 0.9200 1.0800 -10.00%
2010 1.1796 1.3600 1.7700 0.6600 1.2000 -9.09%
2009 1.8837 1.1100 6.2300 0.7700 1.3200 46.67%
2008 5.5478 10.8500 13.3800 0.8300 0.9000 -91.87%
2007 12.6356 8.7700 16.7900 6.6900 11.0700 25.94%
2006 10.4485 9.9900 17.8000 5.2600 8.7900 -10.76%
2005 8.7614 6.3900 11.4700 6.2600 9.8500 45.49%
2004 6.6915 6.7000 7.9500 5.1200 6.7700 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.797B $0.442B
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29